|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The specificity of the elevated transcription of TGF-alpha, TGF-beta, bFGF and flg in glioblastoma cell lines is further suggested by the fact that the transcription of the proto-oncogene c-erbB2, which is overproduced in breast tumor cell lines, was not elevated in glioblastoma cell lines.
|
1347915 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.
|
1347986 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor.
|
1348449 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.
|
1349163 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Scatchard analysis of the binding of recombinant HRG to a breast tumor cell line expressing p185erbB2 showed a single high affinity binding site [dissociation constant (Kd) = 105 +/- 15 picomolar].
|
1350381 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We have studied HER2/neu and c-myc amplification together with steroid receptors in human primary breast tumours and related the outcome with (relapse-free) survival.
|
1356012 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.
|
1358163 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
DNA aneuploidy and p53 or c-erbB-2 expression were simultaneously measured in 29 breast tumours by two-colour flow cytometry.
|
1360329 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A systematic study of primary human breast tumor DNA demonstrated that three proto-oncogenes or regions of the genome (c-myc, int-2, and c-erbB2) are frequently amplified and that there is loss of heterozygosity (LOH) on chromosomes 1p(37%), 1q(20%), 3p(30%), 7(41%), 11p(20%), 13q(30%), 17p(49%), 17q(29%), and 18q(34%).
|
1540899 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
HER-2/neu gene in primary and local metastatic axillary lymph nodes in human breast tumors.
|
1634821 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The ERBB2 proto-oncogene was studied in 539 invasive primary breast tumors and was found amplified (2- greater than 30 copies) in 19%.
|
1671531 |
1991 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
|
1694290 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
|
1920494 |
1991 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The human homolog of the rat neu oncogene, HER2 (also termed c-erbB2) has been demonstrated in amplified form in human breast tumors with poor prognosis.
|
1968437 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Recent work has suggested that overexpression of the HER-2/neu protooncogene may play a role in the aggressive clinical behavior of some breast tumors.
|
1972345 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages.
|
1973070 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In situ hybridisation showed that elevated levels of c-erbB2 mRNA were specific to malignant cells within the breast tumour.
|
2153396 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The c-erbB-2 protooncogene is amplified in 10-40% of primary breast tumors, as well as in breast cancer cell lines; where it is amplified there is increased expression of its product.
|
2188818 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
It is expressed in 92% of breast tumors whereas 69%, 62% and 56% of breast tumors demonstrate significant mRNA levels of c-erbB2, ER and pS2, respectively.
|
2194831 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A newly established metastatic breast tumor cell line with integrated amplified copies of ERBB2 and double minute chromosomes.
|
2487147 |
1989 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar.
|
2566907 |
1989 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Amplification of the human protooncogene c-erbB-2 was found in 12 of 36 human breast tumours and was associated with increased levels of expression of the c-erbB-2 protein, measured both by immunohistological staining and by western blotting.
|
2885574 |
1987 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Fifty-one primary human breast tumors were analyzed for amplification of the c-erbB-2 protooncogene.
|
2893663 |
1988 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA.
|
3285295 |
1988 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.
|
7577462 |
1995 |